APO RESEARCH · REPORT
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug
Selected research
Industry Research
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Research Report 2026
Market perspective
The global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug include Novartis AG, Pfizer Inc, AstraZeneca Plc, Seattle Genetics Inc, NuvOx Pharma LLC, Modus Therapeutics Holding AB, Gilead Sciences Inc and Bristol-Myers Squibb Company, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market by Company
Novartis AG
Pfizer Inc
AstraZeneca Plc
Seattle Genetics Inc
NuvOx Pharma LLC
Modus Therapeutics Holding AB
Gilead Sciences Inc
Bristol-Myers Squibb Company
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Type
SGD-2083
Crizanlizumab
PF-04447943
NVX-508
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Application
Clinic
Hospital
Others
Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- SGD-2083
- Crizanlizumab
- PF-04447943
- NVX-508
- Others
Applications
- Clinic
- Hospital
- Others
Companies covered
- Novartis AG
- Pfizer Inc
- AstraZeneca Plc
- Seattle Genetics Inc
- NuvOx Pharma LLC
- Modus Therapeutics Holding AB
- Gilead Sciences Inc
- Bristol-Myers Squibb Company
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 SGD-2083
- 2.2.3 Crizanlizumab
- 2.2.4 PF-04447943
- 2.2.5 NVX-508
- 2.2.6 Others
- 2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinic
- 2.3.3 Hospital
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Breakdown Data by Type
- 3.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Market Size by Type (2021-2026)
- 3.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Type (2027-2032)
4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Breakdown Data by Application
- 4.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Market Size by Application (2021-2026)
- 4.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Perspective (2021-2032)
- 5.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Growth Trends by Region
- 5.2.1 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Historic Market Size by Region (2021-2026)
- 5.2.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Forecasted Market Size by Region (2027-2032)
- 5.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Dynamics
- 5.3.1 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Trends
- 5.3.2 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Drivers
- 5.3.3 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Challenges
- 5.3.4 Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players by Revenue
- 6.1.1 Global Top Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players by Revenue (2021-2026)
- 6.1.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Revenue Market Share by Players (2021-2026)
- 6.2 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Head Office and Area Served
- 6.4 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Players, Product Type & Application
- 6.5 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Manufacturers Established Date
- 6.6 Global Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
- 7.2 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 7.4 North America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
- 8.2 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 8.4 Europe Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
- 9.2 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
- 10.2 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 10.4 South America Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size (2021-2032)
- 11.2 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novartis AG
- 12.1.1 Novartis AG Company Information
- 12.1.2 Novartis AG Business Overview
- 12.1.3 Novartis AG Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.1.4 Novartis AG Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.1.5 Novartis AG Recent Developments
- 12.2 Pfizer Inc
- 12.2.1 Pfizer Inc Company Information
- 12.2.2 Pfizer Inc Business Overview
- 12.2.3 Pfizer Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.2.4 Pfizer Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.2.5 Pfizer Inc Recent Developments
- 12.3 AstraZeneca Plc
- 12.3.1 AstraZeneca Plc Company Information
- 12.3.2 AstraZeneca Plc Business Overview
- 12.3.3 AstraZeneca Plc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.3.4 AstraZeneca Plc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.3.5 AstraZeneca Plc Recent Developments
- 12.4 Seattle Genetics Inc
- 12.4.1 Seattle Genetics Inc Company Information
- 12.4.2 Seattle Genetics Inc Business Overview
- 12.4.3 Seattle Genetics Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.4.4 Seattle Genetics Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.4.5 Seattle Genetics Inc Recent Developments
- 12.5 NuvOx Pharma LLC
- 12.5.1 NuvOx Pharma LLC Company Information
- 12.5.2 NuvOx Pharma LLC Business Overview
- 12.5.3 NuvOx Pharma LLC Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.5.4 NuvOx Pharma LLC Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.5.5 NuvOx Pharma LLC Recent Developments
- 12.6 Modus Therapeutics Holding AB
- 12.6.1 Modus Therapeutics Holding AB Company Information
- 12.6.2 Modus Therapeutics Holding AB Business Overview
- 12.6.3 Modus Therapeutics Holding AB Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.6.4 Modus Therapeutics Holding AB Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.6.5 Modus Therapeutics Holding AB Recent Developments
- 12.7 Gilead Sciences Inc
- 12.7.1 Gilead Sciences Inc Company Information
- 12.7.2 Gilead Sciences Inc Business Overview
- 12.7.3 Gilead Sciences Inc Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.7.4 Gilead Sciences Inc Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.7.5 Gilead Sciences Inc Recent Developments
- 12.8 Bristol-Myers Squibb Company
- 12.8.1 Bristol-Myers Squibb Company Company Information
- 12.8.2 Bristol-Myers Squibb Company Business Overview
- 12.8.3 Bristol-Myers Squibb Company Revenue in Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Business (2021-2026)
- 12.8.4 Bristol-Myers Squibb Company Vaso-Occlusive Crisis Associated With Sickle Cell Disease Drug Product Portfolio
- 12.8.5 Bristol-Myers Squibb Company Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst